Cover Image

An improvement in sexual function is related to better quality of life, regardless of urinary function improvement: Results from the IDIProst® Gold Study

Tommaso Cai, Giuseppe Morgia, Giuseppe Carrieri, Carlo Terrone, Ciro Imbimbo, Paolo Verze, Vincenzo Mirone, IDIProst® Gold Study Group
  • Tommaso Cai
    Department of Urology, Santa Chiara Regional Hospital, Trento, Italy | ktommy@libero.it
  • Giuseppe Morgia
    Department of Urology and Department of Hygiene and Public Health, University of Catania, Catania, Italy
  • Giuseppe Carrieri
    Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy
  • Carlo Terrone
    Division of Urology, ASO Maggiore della Carità University Hospital, University of Eastern Piedmont, Novara, Italy
  • Ciro Imbimbo
    Department of Urology, University Federico II of Naples, Italy
  • Paolo Verze
    Department of Urology, University Federico II of Naples, Italy
  • Vincenzo Mirone
    Department of Urology, University Federico II of Naples, Italy
  • IDIProst® Gold Study Group
    Affiliation not present

Abstract

Objective. The relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) has recently received increased attention. The aim of this study was to evaluate the efficacy of the Alfa-5® association of Serenoa repens, Pinus massoniana Bark Extract (PMBE) and Crocus sativus (IDIProst® Gold) in improvement of patient’s quality of life, when compared with Serenoa repens alone. Materials and Methods. All patients with clinical and instrumental diagnosis of LUTS due to Benign Prostatic Hyperplasia (BPH) and ED, attending 5 Italians Urological Institutions from May to December 2012 were enrolled in this prospective, multicentre, phase 3 study. Participants were assigned to receive oral capsules of IDIProst® Gold (one capsule q24 h) or Serenoa repens 320 mg (one capsule q24h) for 3 months. Clinical and instrumental analyses were carried out at the enrolment and at the end of therapy. IPSS, IIEF-5 and SF-36 questionnaires have been used. The main outcome measure was the improvement of quality of life at the end of the whole study period. Results. 129 (mean age 45-71 ± 4.36) men were randomly allocated to IDIProst® Gold (n = 83) or Serenoa repens (n = 46). The baseline questionnaire mean scores were 17.1 ± 6.4, 14.9 ± 3.7, 96.3 ± 1.2 for IPSS, IIEF-5 and SF-36, respectively. At the follow-up examination, statistically significant differences have been reported in terms of IPSS (11.9 vs 13.8; p < 0.001), IIEF-5 and SF-36 mean scores (19.3 vs 16.1; 99.7 vs 96.3; p < 0.003; p < 0.001). Moreover, statistically significant differences were then reported between the two visits, in terms of IPSS, IIEF-5 and SF-36 scores (p < 0.003; p < 0.001; p < 0.001), only in the IDIProst® Gold group. Conclusions. In conclusions, we found that IDIProst® Gold significantly improve the quality of life of patients affected by LUTS due to BPH and ED, specifically in terms of sexual function, highlighting that a better sexual quality of life is correlated with an higher overall quality of life regardless of the urinary function.

Keywords

BPH; LUTS; Erectile Dysfunction; Serenoa repens; Crocus sativus; Quality of Life

Full Text:

PDF
Submitted: 2014-01-02 16:18:59
Published: 2013-12-31 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
2424

Views:
PDF
1435

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2013 Tommaso Cai, Giuseppe Morgia, Giuseppe Carrieri, Carlo Terrone, Ciro Imbimbo, Paolo Verze, Vincenzo Mirone, IDIProst® Gold Study Group

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185